Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease

Cardiovascular Research

Volumn 44, Issue 3, 1999, Pages 588-594

  Wang, Xing Li ^a   Oosterhof, Janine ^a   Duarte, Natalia ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atherosclerosis; Coronary disease; Epidemiology; Lipoproteins; Sequence (DNA)

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; AUSTRALIA; BODY MASS; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL MODEL;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; OBESITY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0033434025     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00256-4     Document Type: Article

References (26)

1. Kliewer SA, Willson TM. The nuclear receptor PPARgamma - bigger than fat. Curr Opin Genet Dev 1998;8:576-581.
2. Martin G, Schoonjans K, Staels B, Auwerx J. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998;137(suppl):S75-S80.
3. Brun RP, Tontonoz P, Forman BM et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996;10:974-984.
4. Schoonjans K, Staels B, Auwerx J. The peroxisome peroliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
5. Schoonjans K, Martin G, Staels B, Auwerx J. The peroxisome peroliferator activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-166.
6. Ricote M, Li A, Andrew C et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
7. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
8. Vidal-Puig A, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulatin by insulin and glucocorticoids. J Clin Invest 1997;99:2416-2422.
9. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-1103.
10. Beamer BA, Negri C, Yen CJ et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun 1997;233:756-759.
11. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234.
12. Fajas L, Auboeuf D, Raspe E et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
13. Zhu Y, Qi C, Korenberg JR et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 1995;92:7921-7925.
14. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
15. Flier JS. The adipocyte: storage depot or node on the energy information superhighway. Cell 1995;80:1-18.
16. Hu E, Tontonoz P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc Natl Acad Sci USA 1995;92:9856-9860.
17. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93:229-240.
18. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-252.
19. Ricote M, Huang J, Fajas L et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998;95:7614-7619.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
21. Deeb SS, Fajas L, Nemoto M et al. A Prol2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
22. Ringel J, Engeli S, Distler A, Sharma AM. Prol2Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.
23. Mori Y, Kim-Motoyama H, Katakura T. Effect of the Prol2Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-198.
24. Meirhaeghe A, Fajas L, Helbecque N et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-440.
25. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-959.
26. Wang XL, Liu S-X, McCredie RM, Wilcken DEL. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996;98:372-377.